Vol. 6, Issue 1, Part A (2024)

Background: Erectile Dysfunction (ED) is characterized by the inability to attain and/or sustain an erection of a quality necessary to engage in sexual activity to satisfaction. Our objective was to evaluate the safety and efficacy of Platelet-Rich Plasma (PRP) intracavernosal injection as a novel regenerative therapy for males with.
Methods: This placebo-controlled, prospective, single-blind, randomised clinical trial involved 120 patients with mild to moderate ED as measured by the International Index of Erectile Function (IIEF). The blinded patients were divided into two groups at random: group A (PRP group) and group B (placebo group) (group B). Every patient underwent the following assessments: personal history, sexual history, physical examination (including genital and general examination), laboratory investigations, imaging, and IIEF-5.
Results: Regarding patient satisfaction, neither of these variables exhibited a statistically significant increase over the course of the three time periods examined in the study. With regard to IIEF, there was no statistically significant difference in the treatment group over time. Regarding IIEF, there was no statistically significant difference in the placebo group. There was no statistically critical difference observed between the two groups in terms of evaluation data following treatment for 1, 3, and 6 months.
Conclusions: Treatment of mild to moderate ED with two intracavernosal PRP injections separated by one month is safe, but not more effective than placebo, according to the findings of our clinical trial. Further investigation into patient selection and treatment protocols is required in order to reevaluate these initial findings.